As cancer research increasingly becomes an applied science, academic and biotech researchers interested in general principles must think more about how their efforts translate into the clinical arena. At the same time, researchers on the industrial side stand to gain from a better understanding of the latest strategies for target and lead drug discovery. This way the great promise of new approaches to cancer drug development preventions and treatments that will be less toxic and more effective than current drugs through targeting specific molecular features of aberrant cells can finally be fulfilled.
Molecular Cancer Therapeutics: Strategies for Drug Discovery and Development offers an up–to–date overview of the different phases of drug discovery and preclinical development of new experimental cancer principles. In tying together the diverse set of disciplines and methods involved in these pursuits, the text covers:
- Discovery and validation of drug targets
- Drug screening
- Animal models
- Preclinical testing
- Pharmacology issues
- Clinical concerns
- Intellectual property issues
Directed to a broad audience of students and professionals in academia and industry, Molecular Cancer Therapeutics provides a comprehensive summary of state–of–the–art strategies for identifying drug targets and developing lead inhibitors. With its coverage of target validation, drug screening, and pharmacokinetics, it is an invaluable reference for those working in oncology as well as the broad range of disciplines concerned with drug discovery and development.
Chapter 1. Introduction (G. Prendergast).
Chapter 2. Molecular Cancer Therapeutics: Will the Promise Be Fulfilled? (B. Teicher).
Chapter 3. Cancer Genetics and Drug Target Selection (G. Zhang & W. Kaelin).
Chapter 4. RNA Interference in Mammals: Journey to the Center of Human Disease (P. Paddison & G. Hannon).
Chapter 5. Applications and Issues for Tissue Arrays in Target and Drug Discovery (E. Jonasch, K. Do, C. Logothetis, & T. McDonnell).
Chapter 6. Protein Transduction Strategies for Target and Mechanism Validation (S. Ezhevsky & S. Dowdy).
Chapter 7. Drug Screening: Assay Development Issues (S. Carroll, J. Inglese, S. Mao, & D. Olson).
Chapter 8. Gene Microarray Technologies for Cancer Drug Discovery and Development (R. te Poele, P. Clarke, & P. Workman).
Chapter 9. Transgenic Mouse Models of Cancer (T. Bowen & A. Wynshaw–Boris).
Chapter 10. Transgenic versus Xenograft Mouse Models of Cancer: Utility and Issues (M. Liu, W. Bishop, Y. Wang, & P. Kirschmeier).
Chapter 11. Pharmacodynamic Assays in Cancer Drug Discovery: From Preclinical Validation to Clinical Trial Monitoring (R. Lobell, N. Kohl, & L. Sepp–Lorenzino).
Chapter 12. Pharmacokinetic and Toxicology Issues in Cancer Drug Discovery and Development (P. Benfield & B. Car).
Chapter 13. Clinical Development Issues (S. Averbuch, M. Wolf, B. El–Rayes, & P. LoRusso).
Chapter 14. Intellectual Property and Commercialization Issues in Drug Discovery (L. Malseed).
" this little book represents the ever–so–important 'and' that links research and development together in a logical and thoughtful manner...a valuable resource for scientists and clinicians alike " (
New England Journal of Medicine, January 27, 2005)
"...an excellent publication. I recommended it for libraries...those involved in cancer research...those who teach pharmacy and medical students about drugs used in the treatment of cancer." (The Annals of Pharmacotherapy, December 2004)
" provides an up–to–date overview of the different phases of drug discovery and preclinical development of experimental cancer principles. (Drug Discovery & Development, September 2004)
" a most informative book, discussing the important evolution in the field of cancer therapeutics " (American Journal of Therapeutics, July/August 2004)